Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Vaccine for Smoldering Multiple Myeloma
NCT03631043Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2018
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial in smoldering multiple myeloma (SMM) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Feasibility of Vaccine Development at 12 weeks and Incidence of Adverse Events at 12 months. Started Dec 2018; status: completed.
02
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03631043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631043.